Beckmann
Christoph Beckmann, Walden GB
Patent application number | Description | Published |
---|---|---|
20090209572 | 36-Des(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) Derivatives of Rapamycin for the Treatment of Cancer and Other Disorders - The present invention relates to novel 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections. | 08-20-2009 |
Christoph Hendrik Beckmann, Nr Saffron Walden GB
Patent application number | Description | Published |
---|---|---|
20100081682 | 39-Desmethoxy Derivatives of Rapamycin - The present invention relates to 39-desmethoxyrapamycin derivatives and their uses thereof. The present invention provides for the use of these compounds in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections. | 04-01-2010 |
Christoph Hendrik Beckmann, Vlaardingen NL
Patent application number | Description | Published |
---|---|---|
20100196535 | USE OF PHYTASE IN THE PREPARATION OF A FERMENTED SOY BASED PRODUCT - The present invention relates to a method of preparing a fermented soy-based product, said method comprising: | 08-05-2010 |
Finn Beckmann, Porsgrunn NO
Patent application number | Description | Published |
---|---|---|
20120125201 | SEPARATOR TANK FOR SEPARATING OIL AND GAS FROM WATER - A separator tank ( | 05-24-2012 |
20120132079 | SEPARATOR TANK FOR SEPARATING OIL AND GAS FROM WATER - A separator tank ( | 05-31-2012 |
Flnn Beckmann, Porsgrunn NO
Patent application number | Description | Published |
---|---|---|
20120137888 | SEPARATOR TANK FOR SEPARATING OIL AND GAS FROM WATER - A separator tank ( | 06-07-2012 |
Jacques Beckmann, Rehovot IL
Patent application number | Description | Published |
---|---|---|
20100285600 | Markers associated with the therapeutic efficacy of glatiramer acetate - The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of autoimmune disorders, such as relapsing-remitting multiple sclerosis. The allele-specific responsiveness or non-responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPP1 and IL-12RB2. | 11-11-2010 |
Roland Beckmann, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
Roland Beckmann, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20100056439 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 03-04-2010 |
Roland Beckmann, Vienna AT
Patent application number | Description | Published |
---|---|---|
20100047171 | Fusion Proteins That Contain Natural Junctions - A method for preparing recombinant fusion proteins that comprise at least one natural junction is described. Fusion proteins that contain at least one natural junction have reduced potential for immunogenicity, improved stability, reduced tendency to aggregate, improved expression and/or improved production yields relative to conventional fusion proteins. Novel fusion proteins that comprise at least one natural junction, compositions comprising the fusion proteins and methods of using the proteins are also disclosed. | 02-25-2010 |
20140206846 | Dual Targeting - The present invention relates to antibody-based dual targeting molecules, and to methods for generating such dual targeting molecules, including a library-based approach. | 07-24-2014 |
20140213459 | ANTIBODIES WITH IMPROVED FOLDING STABILITY - The present invention relates to methods for improving the folding stability of antibodies, to antibodies with improved folding stability, nucleic acid and vectors encoding such antibodies, and to uses of such antibodies, nucleic acid and vectors. | 07-31-2014 |
20140255405 | Removal of Monomeric Targets - The present invention relates to a novel method for the removal of monomeric targets from bodily fluids, and to pharmaceutical compositions for use in such methods. | 09-11-2014 |
20150086538 | ANTIBODY LIGHT CHAINS - The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors. | 03-26-2015 |
Roland Beckmann, Wien AT
Patent application number | Description | Published |
---|---|---|
20090208494 | HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31 - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 08-20-2009 |
20120230990 | HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA - The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis. | 09-13-2012 |
20130295611 | HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31 - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 11-07-2013 |
20140186891 | POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 07-03-2014 |
Roland Beckmann, Geneva CH
Patent application number | Description | Published |
---|---|---|
20090081233 | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 03-26-2009 |